Visual Universitätsmedizin Mainz

Maike Knorr, MD

Knorr, MD
Maike Knorr, MD
Position: Physician Cardiology I, Virchow Fellow

maike.knorr@unimedizin-mainz.de
Further Information

Project description

The work program includes the following scientific studies: At the LysMCreiDTR mouse model, where myelomonocytic cells are depleted, a heart attack should be induced by ligation of the anterior coronary artery and ischemia / reperfusion should  be established. Following echocardiography examinations are arranged to determine the left ventricular function, to evaluate the valvular assessment and the contraction behavior. Furthermore, various studies, such as Western blot and real time PCR analysis, immunohistochemical sections and reactive oxygen species measurements for a more detailed characterization of the animals and to clarify the pathophysiological role of myelomonocytic cells in myocardial infarction can be performed in these animals.

Mentor

Mentor of the Virchow-Fellow is Philip Wenzel, MD, Consultant of preclinical research at the Department of Medicine 2.

Team

Curriculum vitae

08/1987 – 06/1991

Loretto Grundschule, Freiburg

08/1991 – 06/2000

Rotteck-Gymnasium, Freiburg, Abitur

08/2000 – 12/2007

Karls-Ruprecht-University Heidelberg, State examination 12/2007

06/2003 – 12/2006

Molecular Experimental Cardiology, Ruprecht-Karls-University, Professor N. Frey, MD

12/2007

Dissertation: „Mögliche Bedeutung eines latenten Energiedefizites in der Pathogenese der hypertrophischen Kardiomyopathie“ (magna cum laude)

01/2008 – 12/2008

Department of Medicine 2, University Medical Center Mainz; Cardiology ward

01/2009 – 06/2009

Hematology, University Medical Center Mainz; Hematology ward

07/2009 – 06/2010

Fellowship by the Foundation Heart of Mainz: „Beeinflussung der Gefässfunktion und der arteriellen Hypertonie im Rahmen einer Angiotensin II Infusion durch in vivo-Ablation von myelomonozytären Zellen“

seit 07/2010

Department of Medicine 2, University Medical Center Mainz; Intensiv Care Unit

References

  • Wenzel P, Rossmann H, Müller C, Kossmann S, Oelze M, Schulz A, Arnold N, Simsek C, Lagrange J, Klemz R, Schönfelder T, Brandt M, Karbach SH, Knorr M, Finger S, Neukirch C, Häuser F, Beutel ME, Kröller-Schön S, Schulz E, Schnabel RB, Lackner K, Wild PS, Zeller T, Daiber A, Blankenberg S, Münzel T. Heme oxygenase-1 suppresses a pro-inflammatory phenotype in monocytes and determines endothelial function and arterial hypertension in mice and humans. European heart journal 36:3437-3446. 2015.

  • Hinkel R, Lange P, Petersen B, Gottlieb E, Ng JK, Finger S, Horstkotte J, Lee S, Thormann M, Knorr M, El-Aouni C, Boekstegers P, Reichart B, Wenzel P, Niemann H, Kupatt C. Heme Oxygenase-1 Gene Therapy Provides Cardioprotection Via Control of Post-Ischemic Inflammation: An Experimental Study in a Pre-Clinical Pig Model. Journal of the American College of Cardiology 66:154-165. 2015.

  • Kossmann S, Hu H, Steven S, Schönfelder T, Fraccarollo D, Mikhed Y, Brähler M, Knorr M, Brandt M, Karbach SH, Becker C, Oelze M, Bauersachs J, Widder J, Münzel T, Daiber A, Wenzel P. Inflammatory monocytes determine endothelial nitric-oxide synthase uncoupling and nitro-oxidative stress induced by angiotensin II. The Journal of biological chemistry 289:27540-27550, 2014.
  • Knorr M, Hausding M, Pfeffer A, Jurk K, Jansen T, Schwierczek K, Oelze M, Kröller-Schön S, Schulz E, Wenzel P, Gori T, Burgin K, Sartor D, Scherhag A, Münzel T, Daiber A. In vitro and in vivo characterization of a new organic nitrate hybrid drug covalently bound to pioglitazone. Pharmacology 93:203-215, 2014.
  • Karbach S, Croxford AL, Oelze M, Schuler R, Minwegen D, Wegner J, Koukes L, Yogev N, Nikolaev A, Reissig S, Ullmann A, Knorr M, Waldner M, Neurath MF, Li H, Wu Z, Brochhausen C, Scheller J, Rose-John S, Piotrowski C, Bechmann I, Radsak M, Wild P, Daiber A, von Stebut E, Wenzel P, Waisman A, Münzel T. Interleukin 17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasis-like skin disease. Arteriosclerosis, thrombosis, and vascular biology 34:2658-2668, 2014.
  • Oelze M, Knorr M, Kröller-Schön S, Kossmann S, Gottschlich A, Rümmler R, Schuff A, Daub S, Doppler C, Kleinert H, Gori T, Daiber A, Münzel T. Chronic therapy with isosorbide-5-mononitrate causes endothelial dysfunction, oxidative stress, and a marked increase in vascular endothelin-1 expression. European heart journal 34:3206-3216, 2013.
  • Mollnau H, Oelze M, Zinssius E, Hausding M, Wu Z, Knorr M, Ghaemi Kerahrodi J, Kröller-Schön S, Jansen T, Teutsch C, Foster C, Li H, Wenzel P, Schulz E, Münzel T, Daiber A. Effects of telmisartan or amlodipine monotherapy versus telmisartan/amlodipine combination therapy on vascular dysfunction and oxidative stress in diabetic rats. Naunyn Schmiedebergs Arch Pharmacol 386:405-419, 2013.
  • Kossmann S, Schwenk M, Hausding M, Karbach SH, Schmidgen MI, Brandt M, Knorr M, Hu H, Kröller-Schön S, Schönfelder T, Grabbe S, Oelze M, Daiber A, Münzel T, Becker C, Wenzel P. Angiotensin II-induced vascular dysfunction depends on interferon-gamma-driven immune cell recruitment and mutual activation of monocytes and NK-cells. Arteriosclerosis, thrombosis, and vascular biology 33:1313-1319, 2013.
  • Kröller-Schön S, Knorr M, Hausding M, Oelze M, Schuff A, Schell R, Sudowe S, Scholz A, Daub S, Karbach S, Kossmann S, Gori T, Wenzel P, Schulz E, Grabbe S, Klein T, Münzel T, Daiber A. Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition. Cardiovasc Res 96:140-149, 2012.